SCIENCE

Sinclair launches blindness reversal trial using age-reset genes

Monday, May 4, 2026 · from 1 podcast, 2 episodes

David Sinclair begins human trials using OSK genes to reverse cellular age in glaucoma patients.
He aims to replace million-dollar gene therapy with an affordable pill, using AI to screen billions of molecules.
Private funding from 70 donors now drives his lab after traditional academic grants were cut.

David Sinclair confirmed his lab is days away from injecting patients with genes designed to reboot their cells to a younger state. The human trial targets blindness from glaucoma, using three Yamanaka factors - OSK - to attempt functional reversal of the optic nerve. This is not about slowing decline. It is an attempt at a literal cellular reset, moving longevity science from theory to a clinical Wright Brothers moment.

"The era of theoretical longevity is ending. David Sinclair confirms his lab is days away from the first human epigenetic reprogramming trials."
- Moonshots with Peter Diamandis

Success in the eye would open the path to systemic age reversal. Sinclair’s lab has already reversed aging in mouse brains, kidneys, and muscles. He argues a true longevity therapeutic should work everywhere, though FDA caution requires a tissue-by-tissue approach for now. The ultimate goal is a pill. Current gene therapy costs between $500,000 and $2 million per treatment. Sinclair is using AI to screen billions of molecules to find a cheap chemical mimic of the OSK effect.

The research nearly stalled. Political friction at Harvard led to the loss of his $1-3 million in annual government grants. In response, Peter Diamandis helped launch ‘Friends of Sinclair Lab,’ a private patronage model that raised $6 million from about 70 members. This pivot highlights a broader frustration with slow, risk-averse academic funding. The model lets the lab move from idea to experiment in weeks, not years.

"Institutional science is too slow for radical breakthroughs. Peter Diamandis and David Sinclair detailed how a funding crisis at Harvard - driven by political friction - nearly shuttered Sinclair's lab."
- Moonshots with Peter Diamandis

Sinclair projects 2026 could be the year human age reversal is proven possible. The private funding ensures his team can run the experiments his AI systems suggest at speed. The bottleneck is no longer hypothesis generation, but execution.

Longevity Biology Health

Peter Diamandis

Source Intelligence

- Deep dive into what was said in the episodes

Moonshots with Peter Diamandis

David Sinclair: The GLP-1 Side Effect No One Talks About, What AI Found in His Lab, and Reversing Blindness | Q&A EP #251 • Apr 28

David Sinclair says emerging data shows GLP-1 drugs benefit the heart and brain beyond weight loss, but notes a rare but serious side effect: about 20,000-30,000 people in the US annually develop sudden blindness, called NAION.
Sinclair states that AI accelerates his lab's work exponentially, enabling drug design by screening billions of molecules and classifying millions of cells as young or old within minutes.
Sinclair cites his own father's health as evidence that lifestyle can override poor genetics, noting his Ashkenazi Jewish ancestors typically died in their 70s.
Sinclair argues mindset is a powerful longevity factor, citing a National Academy of Sciences study that found optimists live 15% longer than pessimists.
Sinclair explains his xenohormesis hypothesis: stressed plants produce polyphenols that signal adversity, activating longevity pathways like SIRT1. He recommends eating colorful vegetables like broccolini.
Sinclair says recent research challenges the old view that genetics determines only 10-15% of lifespan, suggesting the influence may be closer to 50%, but emphasizes at least half of lifespan remains under personal control.
Peter Diamandis frames genetics' role: lifestyle determines health for the first 70-80 years, genetics dominate from 80 to 110, and emerging therapeutics aim to overcome genetic limits.
Sinclair cites evidence that nattokinase is the most natural and powerful method to reverse atherosclerosis, while lowering LDL with drugs like PCSK9 inhibitors can also have reversal effects.
Sinclair details his lab's OSK gene therapy, showing it activates telomerase to lengthen telomeres and is being tested to reverse blindness from NAION, ALS, and macular degeneration in animal models.
Sinclair, prompted by his wife Serena, is now studying the mind-body connection, citing a paper showing brain nerve manipulation affects gut immunity and having a student research sensory nerve rejuvenation.
Sinclair advises investors in longevity biotech to prioritize team reputation and track record, cash runway, and clinical stage, noting capital deficiency is the number one cause of company mortality.
Sinclair references decades of work by Dr. Bhasin showing testosterone does not extend lifespan but prevents falls and supports metabolic health, while clarifying that hormone replacement for women is now considered safe.
Sinclair emphasizes the need to stress the body in an abundance-driven world, advocating for saunas, red light therapy, avoiding plastics, and improving indoor air and water quality.

Health Longevity Biology Models Agents

David Sinclair on the Longevity Pill, Age Reversal Timelines, and Updated Protocols | EP #250 • Apr 27

David Sinclair's lab is days away from the first human epigenetic reprogramming trial, using a subset of three Yamanaka genes (OSK) in the eye of a patient to cure blindness, following successful mouse and monkey trials.
The epigenetic reprogramming technology shows benefits across various tissues in mice, including brain age reversal, memory improvement, and positive effects on motor neurons (ALS models), immune system, muscle, kidney, liver, skin, and joints.
Current human trials for targeted gene therapies, using adeno-associated viruses (AAV) for OSK delivery, typically cost between $500,000 and $2 million per treatment, but Sinclair aims for widespread, affordable application.
The Sinclair Lab developed a small molecule cocktail using AI screening, achieving proof of concept in reversing skin cells from 92-year-olds to a 20-year-old state. This cocktail aims for human clinical trials within months, with potential costs of a few cents per pill at scale.
David Sinclair believes there is no biological or physical law limiting human lifespan, suggesting it's possible to live hundreds or thousands of years by repeatedly resetting cells, akin to how the Wright Brothers’ flight opened possibilities beyond early expectations.
Peter Diamandis initiated the 'Friends of Sinclair Lab' (FOSL) to provide private, direct funding to David Sinclair's research after his government grants, totaling $1-3 million annually, were cut. FOSL has since raised approximately $6 million in annual support from around 70 members.
Sinclair projects that age reversal in humans could be definitively proven as possible as early as 2026, marking a pivotal moment in longevity research.
David Sinclair's personal longevity protocol includes resveratrol (taken with oil for absorption), NMN, and glucose-lowering medications like metformin (1 gram daily) or berberine. He also takes nattokinase (10,000 units daily), which has shown to reverse arterial plaque.
Sinclair emphasizes dietary adjustments like a mostly vegan diet, avoiding processed carbohydrates, and significantly reducing alcohol consumption due to new data linking even one daily glass to smaller brain size. He monitors health with carotid ultrasounds, preferring them over radiation-emitting CT scans.
Maintaining social connections, reducing stress through practices like meditation, and ensuring adequate sleep are crucial for longevity, as loneliness and chronic tension accelerate aging and negatively impact biomarkers like blood pressure and cholesterol.

Longevity Biology Health Startups